AI Schooling and Biotech Scale-Up: Two Questions for GP Diligence

Max: Welcome back to GP Talk. Today, two different bottlenecks: how schools use the day, and how biotech companies move from lab work toward commercial scale.

Maya: One is about students' time; the other, access to equipment. Different problems. Which claims would you take into diligence?

Max: Let's start with the a16z Show episode 'Reinventing School for the AI Era.' Its guests are Joe Liemandt, founder of Alpha School, and Gagan Biyani, co-founder of Academy, also called AJA.

Maya: They challenge the traditional time-based education model and argue for competency-based learning. That's a substantial thesis. What's the mechanism Liemandt says makes a different school day possible?

Max: Liemandt says cognitive science, learning science and LLMs can build an engine teaching children ten times faster than traditional classrooms. That's the technological claim behind the conversation.

Maya: He also reports twice the learning in two daily academic hours, compared with six hours of class plus homework. If core academics take less time, what should fill the rest?

Max: In their account, real-world projects, leadership and teamwork. So the proposal isn't simply a shorter school day. The remaining time becomes part of the educational model.

Maya: They cite the Wharton teamwork simulation, saying fifty percent of MBA students fail because they were never taught teamwork. That's the skills gap they describe.

Max: And Biyani says AJA aims to build positive, high-agency people. 'Agency' is a central ambition in that account. What concrete challenge does he describe for students?

Maya: A five-thousand-dollar travel stipend to encourage solo travel in countries with GDP per person below twenty thousand dollars. That is quite a different kind of learning assignment.

Max: Alpha's entrepreneurship promise is ambitious too. Liemandt describes a guarantee that students will start a business making one million dollars in profit while in high school.

Maya: Liemandt connects his outlook to high standards and motivation, calling high standards key to a child's happiness. What does he say about engagement?

Max: At one Alpha campus, he says sixty-five percent of students prefer school to vacation. He also claims the system improves in quality as it grows. Those are useful claims to follow up.

Maya: There's an interesting note of uncertainty in the same conversation: Liemandt talks about getting through the first year when you don't yet have data. That is worth hearing alongside the promises.

Max: He also forecasts that most learning software will eventually be written by students for their peers. Biyani, meanwhile, says he hears university lectures are now well under ten percent full.

Maya: For an edtech investor, I'd ask how to assess the learning gains, practical projects and student agency. The episode offers a thesis to investigate.

Max: Now let's move from the school day to biotech scale-up. The next source is Elaine Watson's AgFunderNews report on Primient's planned iPROOF facility. The bottleneck here is moving toward commercial scale.

Maya: And the report calls that biotech's 'valley of death.' What is Primient actually proposing to put on the ground? Let's start with the concrete facility details.

Max: Watson reports that iPROOF is scheduled to open in Decatur, Illinois, in May twenty twenty-seven.

Maya: The reported fermenters range from fifteen hundred to ten thousand liters. That is the capacity detail in the report. What else is included alongside the fermentation equipment?

Max: Flexible downstream-processing equipment, or DSP. The report presents the facility as scale-up infrastructure for companies making the move from lab work toward commercial production.

Maya: So I would ask which part of a company's scale-up plan depends on access to equipment like this. The equipment and capacity are concrete starting points for that conversation.

Max: Then comes diligence: what would we need before calling the bottleneck solved? Fermenter capacity alone does not establish a particular startup's commercial outcome.

Maya: Exactly. I'd want to explore the company's actual needs, using the facility's stated fermentation and processing capabilities as the starting point. The report offers specifications, rather than financing or dilution results.

Max: Two very different sources, then: a thesis about how students spend their day, and a proposal for biotech scale-up capacity. Both leave an investor with specific questions worth pursuing.

Maya: For the details, find 'Reinventing School for the AI Era' on the a16z Show, and Watson's iPROOF report in AgFunderNews. That's GP Talk. See you next time.